Children’s Hospital of Philadelphia Develops CAR T-Cell Therapy for Pediatric Solid Tumors: First Human Trial Targets PHOX2B-Derived Peptides

August 2, 2026

Children’s Hospital of Philadelphia (CHOP) USA

Overview

Researchers at Children’s Hospital of Philadelphia (CHOP) are leading the development of CAR T-cell therapies for pediatric solid tumors like neuroblastoma. A ‘peptide-centric’ (PC-CAR) CAR T-cell therapy targeting PHOX2B-derived peptides is undergoing its first human clinical trial, while another CAR T therapy targeting Glypican 2 (GPC2) is nearing completion of Phase I enrollment. Treating solid tumors is significantly more challenging than hematologic cancers, making these novel targets and CAR designs critically important.

In Depth

Key Findings: CHOP Initiates First Human Trial for PHOX2B-Derived Peptide-Targeting PC-CAR T-Cell Therapy in Pediatric Solid Tumors

Researchers at the Children’s Hospital of Philadelphia (CHOP) are making significant strides in developing CAR T-cell therapies for pediatric solid tumors, particularly recurrent neuroblastoma, a notoriously difficult area to treat. Of particular note is the first-ever human clinical trial evaluating a ‘peptide-centric’ (PC-CAR) CAR T-cell therapy designed to specifically target peptides derived from the PHOX2B gene. Furthermore, another CAR T therapy targeting Glypican 2 (GPC2) is close to completing its Phase I enrollment, building a robust pipeline for creating new treatment options for pediatric solid tumors.

Technical and Clinical Details: Novel Targets and CAR Designs to Overcome Solid Tumor Challenges

Innovations in PHOX2B PC-CAR: PHOX2B is a transcription factor overexpressed in neuroblastoma, which has historically been difficult to target directly as a cell surface antigen. CHOP researchers have designed PC-CAR T-cells that leverage the mechanism by which specific PHOX2B-derived peptides are presented on the cell surface via major histocompatibility complex (MHC) molecules. This approach opens the door to targeting intracellular antigens that were previously inaccessible to conventional CAR T therapies.
Promise of GPC2 CAR: Glypican 2 (GPC2) is a cell surface proteoglycan highly expressed in various pediatric solid tumors, including neuroblastoma, making it a highly promising therapeutic target. A CAR T-cell therapy targeting GPC2 is currently in Phase I trials, and its safety and initial efficacy data are eagerly anticipated.
Barriers in Solid Tumor Treatment: Solid tumors present unique challenges for CAR T-cell therapy compared to hematologic cancers, including a complex tumor microenvironment (TME), antigen heterogeneity, and poor homing of CAR T-cells to tumor tissues, leading to limited therapeutic efficacy. CHOP’s research focuses on identifying new targets and designing CARs to overcome these barriers.

Background and Industry Context: Unmet Needs in Pediatric Cancer Treatment

Pediatric cancers, due to their rarity, often suffer from delayed treatment development. In particular, recurrent and refractory solid tumors present a significant unmet need with limited effective treatment options. CHOP, as a specialized pediatric hospital, leading the forefront of CAR T-cell therapy research, is critically important for the advancement of this field. These studies not only hold the potential to dramatically improve the prognosis for pediatric cancer patients but also suggest applicability to adult solid tumor treatments.

Future Outlook: Validation of Safety and Efficacy, and Broad Applications

Safety and initial efficacy data from the ongoing Phase I clinical trials will be essential for evaluating the future potential of these novel PC-CAR and GPC2 CAR T-cell therapies. Further research is particularly needed on the function, infiltration capacity, and long-term persistence of CAR T-cells within the solid tumor microenvironment. If these promising results are confirmed, they could fundamentally change the treatment paradigm for pediatric solid tumors, with potential future expansion to adult solid tumors. CHOP’s efforts are poised to play a crucial role in pioneering the next frontier of CAR T-cell therapy.

Source: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFR0XQXqjQ8gYNfwXD9S8ImOeAsLXl69LjHGrYmU1eJe2o20Y6jwCKmdnbi_PhrsuEUfHC2K6a0lHDo32bMdpaIdjMVK7e6UJSDXpaZMvmdm1PZ1xlWvNiR6kQWtXtA4z1ZdmRIKmaGXqejmHmp92booB2pzBCogQuVVtqS0kQ77zUNomVxDx7UVEPEX5rTXkMJ9VK7zmCKX0WSl23Bw7RiIHWBMaaKLlswa0cnw3xC1QxNrbDAZ1MNOA==

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.